Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colonic Neoplasms 32Rectal Neoplasms 31Colorectal Neoplasms 27Unspecified Adult Solid Tumor, Protocol Specific 15Stomach Neoplasms 10Neoplasm Metastasis 7Lung Neoplasms 6Neuroblastoma 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Medulloblastoma 4Lymphoma, Large B-Cell, Diffuse 4Burkitt Lymphoma 4Unspecified Childhood Solid Tumor, Protocol Specific 3Sezary Syndrome 3Sarcoma 3Rhabdomyosarcoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Liver Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

berzosertib 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Clinical Stage III Gastric Cancer AJCC v8 × Irinotecan × Clear all
NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 14 charts
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡